Lupus News Today Home | Lupus News Today
2024年11月20日 · The Web's Daily Resource for Lupus News
Lupkynis for Lupus Nephritis - Lupus News Today
2023年1月30日 · What is Lupkynis for lupus nephritis? Lupkynis (voclosporin) is an oral therapy approved to treat lupus nephritis, a severe complication of lupus characterized by kidney inflammation and damages. It is marketed by Aurinia Pharmaceuticals.. How does Lupkynis work? Lupkynis works by blocking the activity of a protein called calcineurin. In T-cells, a type of immune cell, blocking calcineurin ...
1st patient enrolled in global Phase 2 trial of daxdilimab for...
2023年5月18日 · A Phase 2 trial evaluating the safety and efficacy of daxdilimab, a potentially first-in-class treatment for people with active, proliferative lupus nephritis (LN) — a lupus complication marked by kidney damage — has enrolled its first patient.
FDA updates Lupkynis label to include long-term efficacy data
2024年5月6日 · The data came from AURORA 2 (NCT03597464), a two-year extension to the one-year Phase 3 AURORA 1 trial (NCT03021499) that looked at how safe Lupkynis is and how well it works in adults with lupus nephritis when given on top of mycophenolate mofetil (MMF) and low-dose corticosteroids.. After three years, more patients on Lupkynis achieved a sustained complete renal response — meaning they had ...
Lupkynis protects kidneys in lupus nephritis for up to 3 years
2023年7月24日 · That’s according to the full results from AURORA 2 (NCT03597464), a Phase 3 extension study that evaluated how safe and well tolerated Lupkynis is and how well it works on top of standard treatment.. In AURORA 2, patients continued to take Lupkynis for two years after completing AURORA 1 (NCT03021499), where they’d …
1st lupus patient treated with CAR T-cell therapy FT819 in early trial
2024年5月16日 · A CAR T-cell approach targeting CD19 was recently validated in an academic investigator-sponsored study, which showed that all patients with lupus-related kidney complications achieved drug-free, durable remission. “The seminal data with autologous CAR-T cell therapy demonstrating early and long-lasting remissions in patients with certain B cell-mediated autoimmune diseases is remarkable ...
Lupkynis approved in Japan to treat lupus nephritis
2024年10月3日 · Lupkynis is designed to lessen the inflammation that drives lupus nephritis, and to support the health and function of kidney cells. It works by blocking the activity of a specific protein, called calcineurin, which is known for its ability to activate T-cells, a type of immune cells involved in inflammation.
Long-term safety of Lupkynis for SLE confirmed in AURORA trial
2023年4月10日 · New top-line data show participants in the Lupkynis treatment arm of the now completed Phase 3 AURORA trial (NCT03021499) had similar kidney biopsy (histologic) findings as those in the active control arm receiving mycophenolate mofetil, an immunosuppressant sold under the brand name CellCept, and low-dose steroids alone.. These results contrast with the well-known kidney-related side effects ...
2 New Meds Found to Change Lupus Nephritis Treatment: Report
2023年1月23日 · Still many patients on high-dose corticosteroids, report finds. The analysis included data from 962 people with the disease in the U.S., as well as insights from 138 rheumatologists — autoimmune disease specialists — and …
Lupkynis helps protect kidneys with lupus nephritis and high...
2023年6月12日 · Lupkynis is approved in the U.S., European Union, and the U.K. as an oral treatment for adults with active lupus nephritis when combined with background immunosuppressant therapy, including mycophenolate mofetil and corticosteroids. It works by blocking the activity of a protein called calcineurin — a mechanism thought to reduce inflammation and stabilize kidney cells.